Biomarker & Intervention Discovery

Ankylosing Spondylitis / Axial Spondyloarthropathy

This page lists 5 druggable gene targets, 54 approved or trial-tested drug candidates and 15 recent clinical trials for Ankylosing Spondylitis / Axial Spondyloarthropathy, with each agent ranked by the strength of its evidence (clinical, mechanistic or correlative). Candidates include existing drugs that could be repurposed. Sources are linked so you can check every claim.

Spontaneous remissionProgressive structural damage (sacroiliac fusion, syndesmophytes) in majority without treatment; spontaneous…
Best-intervention remissionTNF inhibitors (infliximab, adalimumab): ASAS20 response in 60-70%, clinical remission (ASDAS-ID) in 20-40%; IL-17…
Gap sizeLarge — most patients spend years on NSAIDs before biologic assessment; diagnostic delay averages 7-10 years
Primary barrierpractice/access
Full remission profile →
Research Tracker Chronic Disease Interventions Ankylosing Spondylitis / Axial Spondyloarthropathy

Remission & chronicity

Spontaneous remission
Progressive structural damage (sacroiliac fusion, syndesmophytes) in majority without treatment; spontaneous radiographic remission essentially zero; ~10% achieve clinical remission without anti-inflammatory therapy
Best-intervention remission
TNF inhibitors (infliximab, adalimumab): ASAS20 response in 60-70%, clinical remission (ASDAS-ID) in 20-40%; IL-17 inhibitors (secukinumab, ixekizumab): equivalent or superior efficacy; remission rates with early biologics in non-radiographic axSpA may reach 40-50%
Gap size
Large — most patients spend years on NSAIDs before biologic assessment; diagnostic delay averages 7-10 years
Primary barrier
practice/access
Diagnostic delay of 7-10 years from symptom onset is the most significant modifiable factor; MRI-based diagnosis of nr-axSpA (non-radiographic) can enable earlier biologic initiation before structural damage; HLA-B27 testing remains underused in primary care assessment of inflammatory back pain

Biomarker Targets & Therapeutic Agents

Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: Clinical > Mechanistic > Correlative.

HLA-B 50IL17A 72IL23A 8JAK1 189TNF 277

HLA-B

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
CLOZAPINE ? unclear Mechanistic DGIdb
IRINOTECAN HYDROCHLORIDE ? unclear Mechanistic DGIdb
LAPATINIB ? unclear Mechanistic DGIdb
CLINDAMYCIN ? unclear Mechanistic DGIdb
MINOCYCLINE ? unclear Mechanistic DGIdb
INFLIXIMAB ? unclear Mechanistic DGIdb
CARBAMAZEPINE ? unclear Mechanistic DGIdb
MEASLES VACCINE ? unclear Mechanistic DGIdb
DAPSONE ? unclear Mechanistic DGIdb
METHAZOLAMIDE ? unclear Mechanistic DGIdb
BACILLUS CALMETTE-GUERIN ANTIGEN ? unclear Mechanistic DGIdb
FOSPHENYTOIN ? unclear Mechanistic DGIdb
REGORAFENIB ? unclear Mechanistic DGIdb
CARBIMAZOLE ? unclear Mechanistic DGIdb
OXCARBAZEPINE ? unclear Mechanistic DGIdb
MOXIFLOXACIN ? unclear Mechanistic DGIdb
RECOMBINANT INTERFERON ? unclear Mechanistic DGIdb
RIBAVIRIN ? unclear Mechanistic DGIdb
PENICILLIN G POTASSIUM ? unclear Mechanistic DGIdb
SULFAMETHOXAZOLE ? unclear Mechanistic DGIdb
PHENYTOIN SODIUM ? unclear Mechanistic DGIdb
CEFTAZIDIME ANHYDROUS ? unclear Mechanistic DGIdb
LEVOFLOXACIN ANHYDROUS ? unclear Mechanistic DGIdb
OSIMERTINIB ? unclear Mechanistic DGIdb
RITUXIMAB ? unclear Mechanistic DGIdb
STAVUDINE ? unclear Mechanistic DGIdb
ACETAZOLAMIDE ? unclear Mechanistic DGIdb
ABACAVIR ? unclear Mechanistic DGIdb
CIPROFLOXACIN ? unclear Mechanistic DGIdb
THALIDOMIDE ? unclear Mechanistic DGIdb
TRICHLOROETHYLENE ? unclear Mechanistic DGIdb
HYDROXYCHLOROQUINE ? unclear Mechanistic DGIdb
ISONIAZID ? unclear Mechanistic DGIdb
METHIMAZOLE ? unclear Mechanistic DGIdb
PEGINTERFERON ALFA-2A ? unclear Mechanistic DGIdb
AMOXICILLIN ANHYDROUS ? unclear Mechanistic DGIdb
INTERFERON BETA-1A ? unclear Mechanistic DGIdb
SULFAMETHOXAZOLE / TRIMETHOPRIM ? unclear Mechanistic DGIdb
ETANERCEPT ? unclear Mechanistic DGIdb
CLAVULANIC ACID ? unclear Mechanistic DGIdb

Showing top 40 of 50 agents ranked by evidence tier.

IL17A

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
SIMVASTATIN ? unclear Mechanistic DGIdb
IL-12 ? unclear Mechanistic DGIdb
SECUKINUMAB ↓ inhibits Mechanistic DGIdb
TIBULIZUMAB ↓ inhibits Mechanistic DGIdb
BIMEKIZUMAB ↓ inhibits Mechanistic DGIdb
ANTI-IL17A MONOCLONAL ANTIBODY CJM112 ? unclear Mechanistic DGIdb
VUNAKIZUMAB ↓ inhibits Mechanistic DGIdb
M-1095 ↓ inhibits Mechanistic DGIdb
AFASEVIKUMAB ↓ inhibits Mechanistic DGIdb
PERAKIZUMAB ↓ inhibits Mechanistic DGIdb
SIROLIMUS ? unclear Mechanistic DGIdb
GENTAMICIN ? unclear Mechanistic DGIdb
AZATHIOPRINE ? unclear Mechanistic DGIdb
VIDOFLUDIMUS ? unclear Mechanistic DGIdb
COVA322 ? unclear Mechanistic DGIdb
BRODALUMAB ? unclear Mechanistic DGIdb
IXEKIZUMAB ↓ inhibits Mechanistic DGIdb
IZOKIBEP ↓ inhibits Mechanistic DGIdb
REMTOLUMAB ? unclear Mechanistic DGIdb
TETRACYCLINE ? unclear Mechanistic DGIdb
ERYTHROMYCIN ? unclear Mechanistic DGIdb
MANNITOL ? unclear Mechanistic DGIdb
ABBV-257 ? unclear Mechanistic DGIdb
CJM-112 ~ modulates Mechanistic DGIdb
CHEMBL4872876 ↓ inhibits Mechanistic 110.0 nM (Kd) ChEMBL
CHEMBL4858175 ↓ inhibits Mechanistic 12.3 nM (Kd) ChEMBL
CHEMBL4854787 ↓ inhibits Mechanistic 89.0 nM (Kd) ChEMBL
CHEMBL4878993 ↓ inhibits Mechanistic 12.9 nM (Kd) ChEMBL
CHEMBL4869568 ↓ inhibits Mechanistic 6.2 nM (Kd) ChEMBL
CHEMBL4876088 ↓ inhibits Mechanistic 10.1 nM (IC50) ChEMBL
CHEMBL4860250 ↓ inhibits Mechanistic 14.3 nM (IC50) ChEMBL
CHEMBL4866932 ↓ inhibits Mechanistic 10.1 nM (IC50) ChEMBL
CHEMBL4874078 ↓ inhibits Mechanistic 7.0 nM (IC50) ChEMBL
CHEMBL4845695 ↓ inhibits Mechanistic 2.8 nM (IC50) ChEMBL
CHEMBL4855085 ↓ inhibits Mechanistic 4.6 nM (IC50) ChEMBL
CHEMBL4860574 ↓ inhibits Mechanistic 2.0 nM (IC50) ChEMBL
CHEMBL4865978 ↓ inhibits Mechanistic 2.0 nM (IC50) ChEMBL
CHEMBL4870813 ↓ inhibits Mechanistic 1.0 nM (IC50) ChEMBL
CHEMBL4850368 ↓ inhibits Mechanistic 3.0 nM (IC50) ChEMBL
CHEMBL4851738 ↓ inhibits Mechanistic 3.0 nM (IC50) ChEMBL

Showing top 40 of 72 agents ranked by evidence tier.

IL23A

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
USTEKINUMAB ↓ inhibits Mechanistic DGIdb
RISANKIZUMAB ↓ inhibits Mechanistic DGIdb
MIRIKIZUMAB ↓ inhibits Mechanistic DGIdb
BRAZIKUMAB ↓ inhibits Mechanistic DGIdb
TILDRAKIZUMAB ↓ inhibits Mechanistic DGIdb
GUSELKUMAB ↓ inhibits Mechanistic DGIdb
EBDAROKIMAB ↓ inhibits Mechanistic DGIdb
BRIAKINUMAB ↓ inhibits Mechanistic DGIdb

JAK1

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
RUXOLITINIB ↓ inhibits Mechanistic 3.0 nM (IC50) DGIdb
IZENCITINIB ↓ inhibits Mechanistic DGIdb
PEMBROLIZUMAB ? unclear Mechanistic DGIdb
RUXOLITINIB PHOSPHATE ↓ inhibits Mechanistic DGIdb
GOLIDOCITINIB ↓ inhibits Mechanistic DGIdb
FILGOTINIB MALEATE ↓ inhibits Mechanistic DGIdb
MOMELOTINIB ↓ inhibits Mechanistic 11.0 nM (IC50) DGIdb
AZD1480 ↓ inhibits Mechanistic DGIdb
DELGOCITINIB ↓ inhibits Mechanistic DGIdb
TRICETAMIDE ↓ inhibits Mechanistic DGIdb
TOFACITINIB ↓ inhibits Mechanistic 112.0 nM (IC50) DGIdb
PEFICITINIB ↓ inhibits Mechanistic DGIdb
BREPOCITINIB ↓ inhibits Mechanistic DGIdb
UPADACITINIB HEMIHYDRATE ↓ inhibits Mechanistic DGIdb
CYCLOSPORINE ? unclear Mechanistic DGIdb
INCB-047986 ↓ inhibits Mechanistic DGIdb
ABROCITINIB ↓ inhibits Mechanistic DGIdb
ENZASTAURIN ? unclear Mechanistic DGIdb
CERDULATINIB ↓ inhibits Mechanistic DGIdb
NEZULCITINIB ↓ inhibits Mechanistic DGIdb
FILGOTINIB ↓ inhibits Mechanistic DGIdb
GLPG-0555 ↓ inhibits Mechanistic DGIdb
SOLCITINIB ↓ inhibits Mechanistic DGIdb
GUSACITINIB ↓ inhibits Mechanistic DGIdb
ITACITINIB ↓ inhibits Mechanistic DGIdb
BARICITINIB ↓ inhibits Mechanistic DGIdb
MOMELOTINIB DIHYDROCHLORIDE MONOHYDRATE ? unclear Mechanistic Open Targets
DEURUXOLITINIB PHOSPHATE ? unclear Mechanistic Open Targets
TOFACITINIB CITRATE ? unclear Mechanistic Open Targets
UPADACITINIB ? unclear Mechanistic Open Targets
CHEMBL538798 ↓ inhibits Mechanistic 39810.72 nM (IC50) ChEMBL
CHEMBL154580 ↓ inhibits Mechanistic 19952.62 nM (IC50) ChEMBL
SUNITINIB ↓ inhibits Mechanistic 9.2 nM (Kd) ChEMBL
CHEMBL386637 ↓ inhibits Mechanistic 1300.0 nM (IC50) ChEMBL
CHEMBL21156 ↓ inhibits Mechanistic 15.0 nM (IC50) ChEMBL
CHEMBL56543 ↓ inhibits Mechanistic 3380.0 nM (IC50) ChEMBL
DOVITINIB ↓ inhibits Mechanistic 380.0 nM (Kd) ChEMBL
JNJ-7706621 ↓ inhibits Mechanistic 21.0 nM (Kd) ChEMBL
SU-014813 ↓ inhibits Mechanistic 97.0 nM (Kd) ChEMBL
SOTRASTAURIN ↓ inhibits Mechanistic 7300.0 nM (IC50) ChEMBL

Showing top 40 of 189 agents ranked by evidence tier.

TNF

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
NERELIMOMAB ↓ inhibits Mechanistic DGIdb
CROMOLYN SODIUM ? unclear Mechanistic DGIdb
PLACULUMAB ↓ inhibits Mechanistic DGIdb
METHYLENE BLUE ? unclear Mechanistic DGIdb
ALTEPLASE ? unclear Mechanistic DGIdb
CARBOPLATIN ? unclear Mechanistic DGIdb
GENTAMICIN ? unclear Mechanistic DGIdb
GOLIMUMAB ↓ inhibits Mechanistic DGIdb
BUPIVACAINE ? unclear Mechanistic DGIdb
PENTOXIFYLLINE ? unclear Mechanistic 85000.0 nM (IC50) DGIdb
BENZO[E]PYRENE ? unclear Mechanistic DGIdb
THALIDOMIDE ? unclear Mechanistic DGIdb
PYRAZINAMIDE ? unclear Mechanistic DGIdb
GLIMEPIRIDE ? unclear Mechanistic DGIdb
OMEPRAZOLE ? unclear Mechanistic DGIdb
LENERCEPT ↓ inhibits Mechanistic DGIdb
ADALIMUMAB ↓ inhibits Mechanistic DGIdb
PRAZOSIN HYDROCHLORIDE ? unclear Mechanistic DGIdb
REMTOLUMAB ? unclear Mechanistic DGIdb
MIDOSTAURIN ? unclear Mechanistic DGIdb
LENABASUM ? unclear Mechanistic DGIdb
MAGNESIUM SULFATE ANHYDROUS ? unclear Mechanistic DGIdb
PICIBANIL ? unclear Mechanistic DGIdb
FLUOCINOLONE ACETONIDE ? unclear Mechanistic DGIdb
MILTEFOSINE ? unclear Mechanistic DGIdb
HOMIDIUM BROMIDE ? unclear Mechanistic DGIdb
OZORALIZUMAB ↓ inhibits Mechanistic DGIdb
PEGSUNERCEPT ↓ inhibits Mechanistic DGIdb
CERTOLIZUMAB PEGOL ↓ inhibits Mechanistic DGIdb
THERAPEUTIC HORMONE ? unclear Mechanistic DGIdb
NAFAMOSTAT ? unclear Mechanistic DGIdb
FOLIC ACID ? unclear Mechanistic DGIdb
ABBV-257 ? unclear Mechanistic DGIdb
RISPERIDONE ? unclear Mechanistic DGIdb
COVA322 ? unclear Mechanistic DGIdb
HYDROXYCHLOROQUINE ? unclear Mechanistic DGIdb
CERTOLIZUMAB ? unclear Mechanistic DGIdb
AN0128 ? unclear Mechanistic DGIdb
5,7-DIHYDROXY-4-METHYLCOUMARIN ? unclear Mechanistic DGIdb
SORAFENIB ? unclear Mechanistic DGIdb

Showing top 40 of 277 agents ranked by evidence tier.

Clinical Trials

Drug, biologic and supplement trials (treatment or prevention) from ClinicalTrials.gov whose main condition is Ankylosing Spondylitis / Axial Spondyloarthropathy: recruiting, active or completed, most recently updated first. Data retrieved 2026-10-28.

A Phase III Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Active Ankylosing Spondylitis Completed
NCT06378697 Phase: 3 Started: 2023-11-22

This is a randomized, double-blind, placebo-controlled, multi-center phase III clinical study to evaluate the efficacy and safety of AK111 in the treatment of subjects with active ankylosing spondylitis.

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Ankylosing Spondylitis Completed
NCT03928743 Phase: 3 Started: 2019-04-25

The purpose of the study is to demonstrate the efficacy, safety and tolerability of bimekizumab administered subcutaneously (sc) compared to placebo in the treatment of subjects with active ankylosing spondylitis (AS).

Extension Study to Evaluate Safety and Efficacy of Jaktinib in Patients With Active Ankylosing Spondylitis(AS) Completed
NCT05861128 Phase: 3 Started: 2023-11-10

The purpose of this study is to determine if Jaktinib is safe and effective in participants with active ankylosing spondylitis.

Lacticaseibacillus Rhamnosus GG Supplementation in Active Ankylosing Spondylitis Completed
NCT07834788 Phase: N/A Started: 2018-10-01

The goal of this clinical trial was to learn whether Lacticaseibacillus rhamnosus GG supplementation improves disease activity, physical function, and inflammatory markers in adults with active ankylosing spondylitis. The main questions it aimed to answer were: Does Lacticaseibacillus rhamnosus GG s...

Efficacy and Safety Study of Jaktinib in Subjects With Active Ankylosing Spondylitis(AS) Completed
NCT05861102 Phase: 3 Started: 2023-07-20

This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, efficacy and safety study of Jaktinib in subjects with active Ankylosing Spondylitis(AS).

A Clinical Study of JS005 in Patients With Ankylosing Spondylitis Completed
NCT06250062 Phase: 2 Started: 2024-01-13

This is a multicentre, randomized, double-blind, parallel, placebo-controlled Phase II clinical study of 261 adults with active ankylosing spondylitis to evaluate the efficacy and safety of JS005 in the treatment of active ankylosing spondylitis.

A Study Evaluating the Efficacy of Secukinumab 300mg in Chinese Adults With Active Ankylosing Spondylitis Recruiting
NCT05303285 Phase: 4 Started: 2024-06-14

The purpose of this study is to evaluate the safety and efficacy of secukinumab 300mg in Chinese adults participants with active ankylosing spondylitis (AS) who have had an inadequate response to at least 2 non-steroidal anti-inflammatory drugs (NSAIDs) or intolerance to or a contraindication for NS...

Evaluate the Efficacy, Safety, and Pharmacokinetic Profile and Immunogenicity of Subcutaneous Netakimab in Chinese Adult Patients With Active Ankylosing Spondylitis Completed
NCT07277179 Phase: 3 Started: 2023-03-20

The goal of this clinical trial is to To evaluate the efficacy of subcutaneous (SC) Netakimab in adult Chinese patients with Active Ankylosing Spondylitis. Researchers will compare Netakimab to placebo to see if Netakimab works to treat Ankylosing Spondylitis.

A Study to Evaluate the Efficacy and Safety of 608 in Adult Subjects With Active Ankylosing Spondylitis(AS) Recruiting
NCT07261644 Phase: 3 Started: 2025-11-07

This study will evaluate the efficacy and safety of 608 in patients with AS.

A Study to Evaluate Efficacy and Safety of LNK01001 in Adults With Ankylosing Spondylitis Recruiting
NCT07237568 Phase: 3 Started: 2025-08-29

The aim of this study is to evaluate the efficacy and safety of LNK01001 in subjects with active ankylosing spondylitis. The study is comprised of a 16-week randomized, double-blind, parallel-group, placebo-controlled period (the Double-Blind Period); a 36-week open-label, long-term extension period...

International Multicenter Comparative Randomized Placebo-controlled Clinical Study of Efficacy and Safety of BCD-085 in Patients With Ankylosing Spondylitis Completed
NCT03447704 Phase: 3 Started: 2018-02-09

BCD-085-5 is an International, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Study of the Efficacy and Safety of BCD-085. BCD-085 is a monoclonal antibody to interleukin 17. During BCD-085-5 trial patients with active ankylosing spondylitis will receive 120 mg of BCD-085 subcuta...

Comparative Efficacy and Safety of Thalidomide and Sulfasalazine in Moderate to Severe Ankylosing Spondylitis: A Real-World Study From Bangladesh Completed
NCT06985134 Phase: 3 Started: 2017-01-01

the present study was conducted to determine the comparative efficacy and safety of thalidomide and SSZ in moderate to severe cases of ankylosing spondylitis in Bangladesh.

A Study of Comparing Overall Improvement of Patients With Spondyloarthritis Treated With Jitongning Tablets and Placebo Recruiting
NCT06000956 Phase: 3 Started: 2023-09-11

The goal of this clinical trial is evaluating the efficacy and safety of Jitongning tablets in participant population. The main questions it aims to answer are: * Based on the proportion of participants who achieved improvement in ASAS20, evaluate whether the efficacy of Jitongning tablets is superi...

A Study to Evaluate the Long Term Safety and Efficacy of Bimekizumab in Subjects With Ankylosing Spondylitis Completed
NCT03355573 Phase: 2 Started: 2017-11-28

This is a study to assess the long term safety and tolerability of bimekizumab in subjects with ankylosing spondylitis

Study to Demonstrate the Efficacy, Safety and Tolerability of an Intravenous Regimen of Secukinumab Compared to Placebo in Subjects With Active axSpA Completed
NCT04156620 Phase: 3 Started: 2019-12-11

The purpose of this global study was to demonstrate the efficacy, safety, and tolerability of an intravenous (i.v.) regimen of secukinumab compared to placebo in participants with active ankylosing spondylitis (AS) or non-radiographic axial spondyloarthritis (nr-axSpA ) at Week 16 despite current or...

Agents Found By Disease-Level Search

Searched directly from “Ankylosing Spondylitis / Axial Spondyloarthropathy” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 5-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).

54 agents shown (approved or with trial evidence) — 45 not found by the gene-target search above.

Adalimumab

Approved · 7 trials · source: ClinicalTrials.gov, Open Targets
NCT04527380 NCT01768858 NCT01895764

etanercept

Approved · 4 trials · source: ClinicalTrials.gov, Open Targets
NCT00873730 NCT00458185 NCT01793285

Golimumab

Approved · 4 trials · source: ClinicalTrials.gov, Open Targets
NCT02186873 NCT01081717 NCT00265083

Infliximab

Approved · 3 trials · source: ClinicalTrials.gov, Open Targets
NCT01220518 NCT00724529 NCT00936143

Adalimumab, Etanercept, Golimumab or infliximabNOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT01610947 NCT01610947

Certolizumab Pegol

Approved · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT02505542 NCT02154425

Jaktinib Hydrochloride TabletsNOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT04507659 NCT04507659

Enbrel (etanercept)NOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT00421915 NCT00444340

MethotrexateNOT in gene-target list

Phase 3 · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT01313858 NCT01895764

Secukinumab (AIN457) 150 mg s.c.NOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT02763046 NCT02763046

diclophenacNOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT00715091 NCT00715091

PilatesNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05987111

Erector spinae plane block(ESBP)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07633730

Etanercept ® 50 mgNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03033095

Employment and Arthritis: Making it WorkNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01852851

drug treatmentNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01038011

etanercept/placeboNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00873730

Ustekinumab

Phase 3 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT01330901

plantar pressure valuesNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05731635

alendronateNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01104987

Brief InterventionNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02374502

Bimekizumab

Phase 3 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT06668181

Meloxicam suppositoryNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02183168

Meloxicam tabletNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02183168

IndomethacinNOT in gene-target list

Approved · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT02183168

RosuvastatinNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01389388

Celecoxib 200 milligramsNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02528201

Celecoxib 400 milligramsNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02528201

diclofenac 50 milligramsNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02528201

adalimumab (D2E7)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00085644

kunxian capsuleNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00953979

Simponi®NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01313858

wet cupping therapyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05792358

Recombinant humanized IL-17A Monoclonal Antibody（JS005）NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06250062

adalimumab (Humira)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00478660

Augment® Injectable Bone GraftNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01305356

Autologous bone graftNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01305356

systemic non-biological treatmentsNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01081717

anti-TNF biologicsNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01081717

non-anti-TNF biologicsNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01081717

Placebo - Secukinumab (AIN457) 150 mg s.c.NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02763046

Ixekizumab

Phase 3 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT04527380

gumokimab (AK111)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06378697

Hemay005NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05407246

secukinumab (AIN457)NOT in gene-target list

Approved · 1 trial · source: ClinicalTrials.gov
NCT00809159

Anti-TNF agentsNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07453628

NSAIDsNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07453628

Thalidomide 150mgNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02201043

Thalidomide 100mgNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02201043

anti TNF alpha agentNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01361542

Anti TNF alpha therapyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01361542

Golimumab (CNTO 148); placeboNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00265083

Filgotinib

Phase 3 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT03926195

TNF-alpha antagonist and other biotherapyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02886689

Generated by the Open Source Medicine Foundation Biomarker Pipeline — 2026-10-08. Data sources: DGIdb, Open Targets, ChEMBL, PubMed, ClinicalTrials.gov. Not medical advice.